天康生物(002100) - 2020 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2020 was ¥4,703,279,226.34, representing a 73.29% increase compared to ¥2,714,170,240.43 in the same period last year[23]. - The net profit attributable to shareholders of the listed company reached ¥833,796,729.94, a significant increase of 942.09% from ¥80,011,586.86 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was ¥856,324,136.19, up 1,063.01% from ¥73,630,128.00 in the same period last year[23]. - The net cash flow from operating activities was ¥1,223,192,384.23, an increase of 125.58% compared to ¥542,238,516.56 in the previous year[23]. - Basic earnings per share increased to ¥0.78, up 875.00% from ¥0.08 in the same period last year[23]. - The diluted earnings per share was ¥0.77, reflecting an increase of 862.50% from ¥0.08 in the previous year[23]. - The weighted average return on equity rose to 16.64%, up 14.21% from 2.43% in the previous year[23]. - The company achieved total revenue of CNY 4,703.28 million, a year-on-year increase of 73.29%[47]. - The net profit attributable to shareholders reached CNY 833.80 million, up 942.09% compared to the previous year[47]. Business Segments - The feed business generated sales revenue of CNY 1,936.17 million, an increase of 47.89% year-on-year, with sales volume growing by 29.52% to 803,000 tons[47]. - The company's pig farming business reported sales revenue of CNY 1,279.91 million, a significant increase of 167.05% year-on-year, with pig output rising by 4.22% to 425,100 heads[48]. - The pharmaceutical business saw sales revenue of CNY 360.36 million, reflecting a year-on-year growth of 39.75% due to increased government subsidies and higher vaccine prices[48]. - The revenue from the food farming sector surged by 167.05% to ¥1,279,909,931.87, up from ¥479,272,667.52, reflecting a substantial increase in pig prices[58]. - The corn storage business revenue increased by 184.24% to ¥410,397,105.73 from ¥144,383,232.32, showcasing strong market demand[58]. Assets and Investments - Total assets at the end of the reporting period were ¥11,106,418,614.82, a slight decrease of 0.43% from ¥11,154,464,066.40 at the end of the previous year[23]. - The net assets attributable to shareholders of the listed company increased by 15.17% to ¥5,289,743,746.19 from ¥4,592,802,200.06 at the end of the previous year[23]. - Long-term equity investments increased by 2.39% compared to the end of the previous year, primarily due to changes in investments in associated companies[40]. - Fixed assets grew by 5.20% year-on-year, mainly due to the completion of construction projects such as the 200,000-head fattening farm[40]. - Cash and cash equivalents at the end of the reporting period amounted to ¥1,977,325,644, accounting for 17.80% of total assets, a decrease of 5.48% compared to the previous year[66]. - Inventory increased to ¥3,060,637,870, representing 27.56% of total assets, an increase of 4.46% year-on-year due to expanded operational scale[66]. Financial Management - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company reported a significant increase in sales expenses, which rose by 21.15% to ¥216,844,994.81 due to business expansion and changes in transportation methods[54]. - The company's financial expenses increased by 13.14% to ¥94,409,030.40, attributed to increased bank loans for business expansion[54]. - The net increase in cash and cash equivalents was negative at -¥17,881,296.64, a decline of 138.36% compared to an increase of ¥46,613,925.35 in the previous year, mainly due to reduced cash flow from financing activities[54]. Project Investments - The company has cumulative raised funds of ¥981,550,400, with ¥56,951,260 already utilized by June 30, 2020[80]. - The company has decided to terminate the "High-tech Zone North Pharmaceutical Industrial Park Phase II Project" to focus on other projects due to changes in market conditions and strategic needs[84]. - The company aims to improve the efficiency of fund usage and accelerate project implementation to gain market share and competitive advantage[84]. - The "Animal Biosecurity Level 3 Upgrade Project" has a total committed investment of CNY 167.22 million, with CNY 31.58 million invested, achieving 50.56% progress[81]. - The "Gansu Yongchang Pig Farm Phase I Project" has a total committed investment of CNY 90 million, with CNY 15.75 million invested, achieving 80.08% progress[81]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 55,685[186]. - The largest shareholder, Xinjiang Production and Construction Corps State-owned Assets Management Co., held 26.44% of shares, totaling 283,929,184 shares[191]. - The total shares held by the top ten unrestricted common shareholders amounted to 1,000,000,000 shares[191]. - The company did not experience any changes in its controlling shareholder during the reporting period[195]. - The company reported no preferred shares in the reporting period[199]. Compliance and Governance - The company has maintained its independence and compliance with relevant laws and regulations throughout the reporting period[119]. - The company has not undergone any bankruptcy restructuring during the reporting period[128]. - There were no significant litigation or arbitration matters during the reporting period[128]. - The company has implemented an employee stock ownership plan, approved in meetings held on May 29 and June 15, 2020[132]. - The half-year financial report has not been audited[125].